Welcome to our dedicated page for SELLAS Life Sciences Group news (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on SELLAS Life Sciences Group stock.
SELLAS Life Sciences Group, Inc. develops novel cancer therapeutics as a late-stage clinical biopharmaceutical company. News about SLS centers on its acute myeloid leukemia programs, including galinpepimut-S (GPS), a WT1-directed peptide immunotherapy evaluated in the REGAL Phase 3 trial, and SLS009 (tambiciclib), a selective CDK9 inhibitor studied in AML settings.
Recurring updates include clinical and preclinical data presentations, trial progress, regulatory and corporate updates, financial results, cash-position disclosures, warrant exercises, and other capital-structure developments tied to funding its oncology pipeline.
SELLAS Life Sciences (NASDAQ: SLS), a late-stage clinical biopharmaceutical company, has appointed Dr. Linghua Wang to its Scientific Advisory Board. Dr. Wang, a tenured Associate Professor at MD Anderson's Department of Genomic Medicine, brings extensive expertise in cancer immunogenomics and computational biology.
Dr. Wang leads the Computational Biology Laboratory at MD Anderson and holds multiple prestigious positions, including Associate Member of The James P. Allison Institute. Her research focuses on understanding tumor ecosystems using advanced technologies like single-cell and spatial omics, AI-driven pathology, and machine learning. With over 100 publications and multiple NIH/NCI grants, her expertise aligns with SELLAS's focus on translational research and precision medicine.
SELLAS Life Sciences (NASDAQ: SLS), a late-stage clinical biopharmaceutical company, announced its upcoming addition to the Russell 3000® and Russell 2000® Indexes, effective June 27, 2025. This inclusion marks a significant milestone for the company, reflecting its progress in pipeline development.
The Russell 3000® Index tracks the top 3,000 U.S. public companies, while the Russell 2000® Index focuses on small-cap stocks representing about 10% of the U.S. equity market capitalization. The company is approaching key milestones, including topline Phase 2 data readout for SLS009 in acute myeloid leukemia (AML) and final analysis of the Phase 3 REGAL trial of GPS in AML.
SELLAS Life Sciences Group (NASDAQ: SLS), a late-stage clinical biopharmaceutical company specializing in cancer therapy development, has announced its participation in the upcoming A.G.P. Virtual Healthcare Company Showcase. The company's President and CEO, Dr. Angelos Stergiou, will engage in a fireside chat scheduled for Wednesday, May 21, 2025, at 8:20 am ET.
SELLAS Life Sciences (NASDAQ: SLS) has announced the dosing of its first pediatric patient in the ongoing Phase 2 trial of SLS009 (tambiciclib) for relapsed/refractory acute myeloid leukemia (r/r AML). The trial evaluates SLS009, a highly selective CDK9 inhibitor, in combination with venetoclax and azacitidine at 45mg and 60mg dose levels. The company received FDA Rare Pediatric Disease Designation (RPDD) in July 2024, making it eligible for a Priority Review Voucher upon potential NDA approval, which could be worth approximately $100 million.
The Phase 2 trial targets a 20% response rate with a median survival of at least 3 months. The study includes additional cohorts for ASXL1-mutated AML patients and those with myelodysplasia-related molecular abnormalities.
SELLAS Life Sciences (NASDAQ: SLS) reported significant progress in Q1 2025, highlighted by positive results from their Phase 2 trial of SLS009 in relapsed/refractory AML. The trial showed remarkable median overall survival of 8.9 months in AML-MRC patients and 8.8 months in venetoclax-resistant patients, substantially exceeding historical benchmarks of 2.5 months. The drug achieved a 67% overall response rate in AML-MRC patients.
The company's Phase 3 REGAL trial of GPS in AML showed promising interim results with median survival exceeding 13.5 months versus historical 6 months. Financial results showed reduced losses with Q1 net loss of $5.8 million ($0.07 per share) compared to $9.6 million in Q1 2024. SELLAS maintained a strong financial position with $28.4 million cash as of March 31, 2025, plus additional $4.0 million from warrant exercises in April 2025.
SELLAS Life Sciences Group (NASDAQ: SLS) has presented breakthrough preclinical data for SLS009 in treating TP53 mutated Acute Myeloid Leukemia (AML) at the 2025 AACR Conference. The study shows that SLS009, a selective CDK9 inhibitor, reduced TP53-mutated leukemia cells by up to 97% in combination with azacitidine-venetoclax, and 80% as monotherapy.
In ongoing Phase 2 trials, patients receiving 30mg of SLS009 BIW achieved a median overall survival of 8.8 months, significantly exceeding the historical benchmark of 2.5 months. Response rates were notable across various mutations: 67% for ASXL1, 60% for RUNX1, and 33% for TP53.
SELLAS Life Sciences Group (NASDAQ: SLS) has announced its upcoming presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled for May 30-June 3, 2025. The presentation will showcase preclinical efficacy data of SLS009 (tambiciclib) in ASXL1 mutated colorectal cancer.
The poster presentation, scheduled for June 2, 2025 (1:30 PM-4:30 PM CDT), will be displayed in Hall A under abstract #3121. The full abstract will be released on ASCO's website on May 22, 2025. Currently, SLS009 is undergoing a Phase 2 clinical trial evaluating its safety and efficacy in combination with venetoclax and azacitidine for AML patients with ASXL1 mutations.
SELLAS Life Sciences Group (NASDAQ: SLS) has announced positive results from Cohort 3 of its Phase 2 trial of SLS009 (tambiciclib) in relapsed/refractory acute myeloid leukemia (r/r AML). The trial showed remarkable survival benefits with a median Overall Survival (mOS) of 8.8 months in patients relapsed or refractory to venetoclax-based regimens, significantly exceeding the historical benchmark of 2.5 months.
The study enrolled 14 r/r AML patients, with 71% having AML-MRC. Key findings include an Overall Response Rate (ORR) of 67% in AML-MRC patients and 46% in all evaluable patients, surpassing the targeted 20% ORR. Notable response rates were observed across different genetic mutations: 67% in ASXL1, 60% in RUNX1, and 33% in TP53 patients.
The trial continues with expansion cohorts 4 and 5, focusing on AML-MRC patients with various mutations. Full data and FDA regulatory path feedback are expected in 1H 2025.